Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesco Merli

Showing results (141-150 of 156) with videos related to

Pageof 16
Sort By:
Blood Advances|June 25, 2026
Renoir phase III Rituximab-Lenalidomide vs Rituximab as Maintenance Treatment in Relapsed/Refractory Follicular LymphomaBarbara Botto, Carola Boccomini, Andrea Evangelista, et al.
Hematological Oncology|October 20, 2022
SARS-CoV-2 infection in patients with chronic lymphocytic leukemia: The Italian Hematology Alliance on COVID-19 cohortMichele Merli, Isacco Ferrarini, Francesco Merli, et al.
Hemasphere|April 10, 2023
Role of Rituximab Addition to First-line Chemotherapy Regimens in Nodular Lymphocyte-predominant Hodgkin Lymphoma: A Study by Fondazione Italiana LinfomiManuel Gotti, Roberta Sciarra, Alessandro Pulsoni, et al.
Blood|September 12, 2025
Impact of immunochemotherapy regimens on outcomes of patients with primary mediastinal B-cell lymphoma in the IELSG37 trialEmanuele Zucca, Luca Ceriani, Giovannino Ciccone, et al.
Lancet (London, England)|December 24, 2019
Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trialViola Poeschel, Gerhard Held, Marita Ziepert, et al.
The Lancet. Haematology|September 20, 2025
Rituximab, bendamustine, and cytarabine followed by venetoclax in older patients with high-risk mantle cell lymphoma (FIL_V-RBAC): a multicentre, single-arm, phase 2 studyCarlo Visco, Valentina Tabanelli, Maria Vittoria Sacchi, et al.
Cancers|March 28, 2024
Real-World Outcome of Treatment with Single-Agent Ibrutinib in Italian Patients with Chronic Lymphocytic Leukemia: Final Results of the EVIdeNCE StudyFrancesca Romana Mauro, Potito Rosario Scalzulli, Lydia Scarfò, et al.
Hemasphere|July 10, 2023
Radiation and Dose-densification of R-CHOP in Aggressive B-cell Lymphoma With Intermediate Prognosis: The UNFOLDER StudyLorenz Thurner, Marita Ziepert, Christian Berdel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 12, 2021
Simplified Geriatric Assessment in Older Patients With Diffuse Large B-Cell Lymphoma: The Prospective Elderly Project of the Fondazione Italiana LinfomiFrancesco Merli, Stefano Luminari, Alessandra Tucci, et al.
Haematologica|February 22, 2024
IELSG38: phase II trial of front-line chlorambucil plus subcutaneous rituximab induction and maintenance in mucosa-associated lymphoid tissue lymphomaAnastasios Stathis, Maria Cristina Pirosa, Lorella Orsucci, et al.
Pageof 16

Showing results (141-150 of 156) with videos related to

Sort By:
Pageof 16
Blood Advances|June 25, 2026
Renoir phase III Rituximab-Lenalidomide vs Rituximab as Maintenance Treatment in Relapsed/Refractory Follicular LymphomaBarbara Botto, Carola Boccomini, Andrea Evangelista, et al.
Hematological Oncology|October 20, 2022
SARS-CoV-2 infection in patients with chronic lymphocytic leukemia: The Italian Hematology Alliance on COVID-19 cohortMichele Merli, Isacco Ferrarini, Francesco Merli, et al.
Hemasphere|April 10, 2023
Role of Rituximab Addition to First-line Chemotherapy Regimens in Nodular Lymphocyte-predominant Hodgkin Lymphoma: A Study by Fondazione Italiana LinfomiManuel Gotti, Roberta Sciarra, Alessandro Pulsoni, et al.
Blood|September 12, 2025
Impact of immunochemotherapy regimens on outcomes of patients with primary mediastinal B-cell lymphoma in the IELSG37 trialEmanuele Zucca, Luca Ceriani, Giovannino Ciccone, et al.
Lancet (London, England)|December 24, 2019
Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trialViola Poeschel, Gerhard Held, Marita Ziepert, et al.
The Lancet. Haematology|September 20, 2025
Rituximab, bendamustine, and cytarabine followed by venetoclax in older patients with high-risk mantle cell lymphoma (FIL_V-RBAC): a multicentre, single-arm, phase 2 studyCarlo Visco, Valentina Tabanelli, Maria Vittoria Sacchi, et al.
Cancers|March 28, 2024
Real-World Outcome of Treatment with Single-Agent Ibrutinib in Italian Patients with Chronic Lymphocytic Leukemia: Final Results of the EVIdeNCE StudyFrancesca Romana Mauro, Potito Rosario Scalzulli, Lydia Scarfò, et al.
Hemasphere|July 10, 2023
Radiation and Dose-densification of R-CHOP in Aggressive B-cell Lymphoma With Intermediate Prognosis: The UNFOLDER StudyLorenz Thurner, Marita Ziepert, Christian Berdel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 12, 2021
Simplified Geriatric Assessment in Older Patients With Diffuse Large B-Cell Lymphoma: The Prospective Elderly Project of the Fondazione Italiana LinfomiFrancesco Merli, Stefano Luminari, Alessandra Tucci, et al.
Haematologica|February 22, 2024
IELSG38: phase II trial of front-line chlorambucil plus subcutaneous rituximab induction and maintenance in mucosa-associated lymphoid tissue lymphomaAnastasios Stathis, Maria Cristina Pirosa, Lorella Orsucci, et al.
Pageof 16